Login / Signup

Targeting tumor vulnerabilities associated with loss of heterozygosity.

Veronica RendoIvaylo StoimenovTobias Sjöblom
Published in: Molecular & cellular oncology (2020)
We show that N-acetyltransferase 2 (NAT2) loss of heterozygosity can be targeted in >4% of colorectal cancers with the use of a small molecule. We identify and describe the effect of a compound that impairs the growth of colorectal tumors with slow NAT2 activity by half when compared to wild-type.
Keyphrases
  • wild type
  • small molecule
  • cancer therapy
  • protein protein
  • drug delivery
  • young adults